BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26588187)

  • 1. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
    Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
    SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
    Wu D; Gu Q; Zhao N; Xia F; Li Z
    J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
    Feng WF; Zhao YB; Huang W; Yang YZ
    J Enzyme Inhib Med Chem; 2010 Aug; 25(4):459-66. PubMed ID: 19951006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains.
    Zhao Y; Feng W; Yang Y; Ling L; Chen R
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(6):637-9. PubMed ID: 17357475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The P2/P2' sites affect the substrate cleavage of TNF-α converting enzyme (TACE).
    Liu S; Liu S; Wang Y; Liao Z
    Mol Immunol; 2014 Nov; 62(1):122-8. PubMed ID: 24980871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
    Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
    Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.
    Yang JS; Chun K; Park JE; Cho M; Seo J; Song D; Yoon H; Park CH; Joe BY; Choi JH; Kim MH; Han G
    Bioorg Med Chem; 2010 Dec; 18(24):8618-29. PubMed ID: 21078557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
    Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation and docking study of maleimide derivatives bearing benzenesulfonamide as selective COX-2 inhibitors and anti-inflammatory agents.
    Firke SD; Bari SB
    Bioorg Med Chem; 2015 Sep; 23(17):5273-81. PubMed ID: 26277757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sheppeck JE; Gilmore JL; Yang A; Chen XT; Xue CB; Roderick J; Liu RQ; Covington MB; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1413-7. PubMed ID: 17188863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel methods and strategies in the discovery of TACE inhibitors.
    Murumkar PR; Giridhar R; Yadav MR
    Expert Opin Drug Discov; 2013 Feb; 8(2):157-81. PubMed ID: 23231541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
    Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
    J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex.
    Wisniewska M; Goettig P; Maskos K; Belouski E; Winters D; Hecht R; Black R; Bode W
    J Mol Biol; 2008 Sep; 381(5):1307-19. PubMed ID: 18638486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
    Pirard B; Matter H
    J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
    Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
    Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
    Govinda Rao B; Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Tian SK; Saunders JO
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2250-3. PubMed ID: 17289381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
    Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.